tiprankstipranks
Trending News
More News >

Pyxis Oncology Appoints New Principal Financial Officer

Story Highlights
Pyxis Oncology Appoints New Principal Financial Officer

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Pyxis Oncology ( (PYXS) ).

On July 1, 2025, Pyxis Oncology, Inc. announced the retirement of Pamela Connealy, their Chief Financial Officer and Chief Operating Officer. Her departure was amicable and not due to any disagreements with the company’s management or auditors. Following her retirement, Jitendra Wadhane, the current Senior Vice President Finance and Chief Accounting Officer, was appointed as the Principal Financial Officer. Mr. Wadhane will maintain his current roles without additional compensation.

The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.

Spark’s Take on PYXS Stock

According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.

Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.

To see Spark’s full report on PYXS stock, click here.

More about Pyxis Oncology

Average Trading Volume: 568,404

Technical Sentiment Signal: Sell

Current Market Cap: $66.9M

See more insights into PYXS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1